<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Differentiated thyroid cancer: Overview of management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Differentiated thyroid cancer: Overview of management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Differentiated thyroid cancer: Overview of management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">R Michael Tuttle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Surgery is the primary mode of therapy for patients with differentiated thyroid cancer, followed by radioiodine therapy (when indicated) and thyroid hormone suppression therapy. After initial surgery, patients with thyroid cancer are typically managed by endocrinologists specializing in the treatment of thyroid cancer.</p><p>This topic will provide a broad overview of the therapeutic options for patients with differentiated thyroid cancer. The specific therapies for differentiated thyroid cancer are reviewed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2191.html" rel="external">"Differentiated thyroid cancer refractory to standard treatment: Systemic therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Thyroid cancer'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Thyroid follicular epithelial-derived cancers are divided into three categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Papillary cancer – 85 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Follicular cancer – 12 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Anaplastic (undifferentiated) cancer – &lt;3 percent</p><p></p><p>Papillary and follicular cancers are considered differentiated cancers, and patients with these tumors are often treated similarly, despite numerous biologic differences. Most anaplastic (undifferentiated) cancers appear to arise from differentiated cancers. The treatment of anaplastic thyroid cancer is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2189.html" rel="external">"Anaplastic thyroid cancer"</a>.)</p><p>Other malignant diseases of the thyroid include medullary thyroid cancer (MTC) (which can be familial, either as part of the multiple endocrine neoplasia type 2 [MEN2] syndrome or isolated familial MTC) and primary thyroid lymphoma. Cancers that metastasize to the thyroid include breast, colon, renal cancer, and melanoma. (See  <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H13330461"><span class="h1">GUIDELINES</span><span class="headingEndMark"> — </span>The American Thyroid Association (ATA) published evidence-based guidelines in 2015 for the staging and management of differentiated thyroid cancer [<a href="#rid1">1</a>]. In addition, guidelines have been published by the National Comprehensive Cancer Network (NCCN) [<a href="#rid2">2</a>] and a European consensus group [<a href="#rid3">3</a>]. Our approach below is largely consistent with the ATA and NCCN guidelines [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H4"><span class="h1">SURGICAL MANAGEMENT</span><span class="headingEndMark"> — </span>Surgery is the primary mode of therapy for patients with differentiated thyroid cancer. Preoperative ultrasound is important for planning the surgical procedure. In the absence of prospective trials, conclusions regarding the optimal surgical approach are based upon retrospective analyses and expert consensus opinions [<a href="#rid1">1,3-7</a>].</p><p>After initial surgery, patients with thyroid cancer are typically managed by endocrinologists specializing in the treatment of thyroid cancer.</p><p class="headingAnchor" id="H2213063148"><span class="h2">Preoperative imaging</span><span class="headingEndMark"> — </span>All patients should have a preoperative ultrasound evaluation of the central and lateral neck lymph nodes in order to plan the surgical procedure. Additional imaging beyond routine preoperative neck ultrasound should be obtained in patients presenting with locally advanced disease. The role of preoperative imaging in determining the surgical approach is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Importance of preoperative imaging'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Choice of surgical procedure</span><span class="headingEndMark"> — </span>Surgery is the primary mode of therapy for patients with differentiated thyroid cancer. Surgery should be performed by an experienced thyroid surgeon to minimize the risk of hypoparathyroidism and recurrent laryngeal nerve (RLN) injury. In one study, complications were lower when surgery was performed by surgeons performing at least 25 thyroidectomies per year [<a href="#rid8">8</a>].</p><p>The operative approach depends upon the extent of the disease (eg, primary tumor size and the presence of extrathyroidal extension or lymph node metastases), the patient's age, and the presence of comorbid conditions. The choice of procedure is discussed briefly below and in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Choice of procedure'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor &lt;1 cm without extrathyroidal extension and no lymph nodes</strong> – When surgery is planned for unilateral intrathyroidal differentiated thyroid cancer &lt;1 cm, a thyroid lobectomy is preferred unless there are clear indications to remove the contralateral lobe (eg, clinically evident thyroid cancer in the contralateral lobe, previous history of head and neck radiation, strong family history of thyroid cancer, or imaging abnormalities that will make follow-up difficult).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor 1 to 4 cm without extrathyroidal extension and no lymph nodes</strong> – For intrathyroidal tumors between 1 and 4 cm, the initial surgical procedure can either be a total thyroidectomy or thyroid lobectomy. Total thyroidectomy would be chosen either based on patient preference, the presence of ultrasonographic abnormalities in the contralateral lobe (nodules, thyroiditis in the contralateral lobe, or nonspecific lymphadenopathy that will make follow-up difficult), or on a decision by the treatment team that radioiodine therapy may be beneficial either as adjuvant therapy or to facilitate follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor ≥4 cm, extrathyroidal extension, or metastases </strong>– Total thyroidectomy is recommended if the primary tumor is 4 cm in diameter or greater, there is extrathyroidal extension of tumor, or there are metastases to lymph nodes or distant sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Any tumor size and history of childhood head and neck radiation</strong> – Total thyroidectomy should also be performed in all patients with thyroid cancer who have a history of exposure to ionizing radiation of the head and neck, given the high rate of tumor recurrence with lesser operations in these patients [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/7059.html" rel="external">"Radiation-induced thyroid disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multifocal papillary microcarcinoma (fewer than five foci)</strong> – Unilateral lobectomy and isthmusectomy is an appropriate procedure for patients whose pathology reports subsequently show multifocal papillary microcarcinomas with fewer than five foci.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multifocal papillary microcarcinoma (more than five foci)</strong> – When multifocal papillary cancer is appreciated preoperatively, particularly when a large number of microcarcinoma are suspected (eg, greater than five foci, especially if the foci are in the 8 to 9 mm size range), we are more likely to perform a total thyroidectomy.</p><p></p><p class="bulletIndent1">For patients whose initial procedure was a lobectomy and in whom pathology shows multifocal papillary microcarcinomas with more than five foci, especially if the foci are in the 8 to 9 mm range, we typically refer patients for completion thyroidectomy.</p><p></p><p>The approach to lymph node dissection is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Approach to lymph node dissection'</a> and  <a class="medical medical_review" href="/z/d/html/15033.html" rel="external">"Neck dissection for differentiated thyroid cancer"</a>.)</p><p class="headingAnchor" id="H2976327189"><span class="h2">Postoperative complications</span><span class="headingEndMark"> — </span>The management of potential metabolic (eg, hypoparathyroidism) and anatomic (eg, laryngeal nerve damage) postsurgical complications is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H2115783455"><span class="h2">Postoperative thyroid hormone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lobectomy</strong> – For low- and intermediate-risk patients whose initial surgery was a lobectomy, we do not begin thyroid hormone (T4) immediately postoperatively (unless the patient has Hashimoto's thyroiditis and the preoperative thyroid-stimulating hormone [TSH] was high normal) [<a href="#rid10">10</a>]. Instead, we measure serum TSH six weeks after surgery and determine the need for T4 based upon the TSH and evaluation of postoperative disease status. Following lobectomy, a TSH between 0.5 and 2 mIU/mL is considered acceptable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total thyroidectomy</strong> – After total thyroidectomy, all patients require postoperative thyroid hormone therapy (T4 [<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>]) to replace normal hormone production and/or to suppress regrowth of tumor. The initial dose and type of thyroid hormone (T4 or T3 [<a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a>]) depend upon the likelihood of needing radioiodine scanning/ablation and the method of preparation for radioiodine scanning. These decisions are based upon the estimated risk of persistent/recurrent disease. In the immediate postoperative period, complete clinicopathologic findings may be unavailable to fully estimate these risks, and the clinician may need to modify dosing four to six weeks postoperatively. (See <a class="local">'Initial risk stratification'</a> below.)</p><p></p><p class="bulletIndent1">T4 (usually 1.6 to 2 mcg/kg per day) can be started immediately postoperatively in the following patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>American Thyroid Association (ATA) low- and intermediate-risk patients  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) who are unlikely to need radioiodine scanning or ablation. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Patient selection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Selected ATA intermediate- and high-risk patients  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) in whom radioiodine scanning and ablation will be done using recombinant human TSH (rhTSH [thyrotropin alfa]). (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Choice of method for increasing TSH'</a>.)</p><p></p><p class="bulletIndent1">The higher doses are used in selected intermediate- and high-risk patients, modified by age and other comorbid conditions. TSH is measured four to six weeks postoperatively, and the dose is adjusted as needed to achieve goal TSH. The initial TSH goal is based upon the risk of recurrence as determined by clinicopathologic findings and postoperative thyroglobulin (Tg). (See <a class="local">'Thyroid hormone suppression'</a> below.)</p><p></p><p class="bulletIndent1">The long-term TSH goals depend upon structural and biochemical response to initial therapy, which is determined by ongoing assessment and risk stratification. (See <a class="local">'Dynamic risk stratification'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom radioiodine scanning and ablation will be done using thyroid hormone withdrawal (typically ATA high-risk patients), short-term thyroid hormone replacement can be initiated postoperatively with T3, 25 mcg two to three times daily. After two to three weeks, T3 is discontinued and imaging is performed once the patient's serum TSH concentration is above 25 to 30 mU/L.</p><p></p><p class="bulletIndent2">Another alternative is simply to withhold any thyroid hormone therapy until the patient's serum TSH concentration is above 30 mU/L. These options are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Choice of method for increasing TSH'</a>.)</p><p></p><p class="headingAnchor" id="H477971730"><span class="h1">INITIAL RISK STRATIFICATION</span><span class="headingEndMark"> — </span>After surgery, the presence or absence of persistent disease and risk for recurrent disease should be assessed in order to determine the need for additional treatment, in particular radioiodine therapy.</p><p class="headingAnchor" id="H2776274501"><span class="h2">Postoperative evaluation</span><span class="headingEndMark"> — </span>We typically obtain a serum TSH and a nonstimulated serum thyroglobulin (Tg) approximately four to six weeks after thyroidectomy or lobectomy in order to better define the postoperative disease status.</p><p>While we agree with the American Thyroid Association (ATA) guidelines that the optimal cutoff value for either a stimulated or nonstimulated postoperative Tg four to six weeks after surgery is not clearly established [<a href="#rid1">1</a>], we expect nonstimulated Tg values of:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;5 ng/mL after a total thyroidectomy</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;30 ng/mL after thyroid lobectomy</p><p></p><p>Serum Tg values above these cutoffs should prompt reevaluation of the completeness of the initial surgery (usually with neck ultrasonography) and consideration of the possibility of persistent metastatic disease.</p><p>Diagnostic (pre-radioiodine treatment) whole-body scans for localization of persistent disease before remnant ablation, adjuvant radioiodine therapy, or radioiodine treatment of metastatic thyroid cancer are performed less often. They can be performed when the extent of residual disease cannot be determined from surgery and neck ultrasonography and when the presence of residual disease may alter the decision to treat with radioiodine or the administered activity [<a href="#rid1">1</a>]. However, because almost all patients have thyroid remnants, our approach is to omit the pre-radioiodine treatment diagnostic scan, administer empiric therapeutic doses of iodine-131 (131-I) therapy (based upon surgical and ultrasonography findings), and obtain only a post-radioiodine treatment scan for localization of uptake. (See <a class="local">'Radioiodine therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Pretreatment scanning'</a>.)</p><p class="headingAnchor" id="H2272967712"><span class="h2">Risk classification</span><span class="headingEndMark"> — </span>The clinicopathologic features of each case are important for providing prognostic information. Since the tumor, node, metastases (TNM) staging system is designed to stratify risk based upon disease-specific mortality and may not accurately predict the risk of recurrence/persistent disease in thyroid cancer, we use TNM staging  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>) to estimate mortality and the ATA risk stratification system to estimate the risk of recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>).</p><p>Staging is reviewed briefly below and in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNM staging system</strong> – Formal disease staging is based upon applying the individual TNM descriptors in the American Joint Commission on Cancer (AJCC) staging scheme  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'TNM system'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATA risk stratification system</strong> – We use the ATA initial risk stratification system to estimate the risk of persistent/recurrent disease. This system is designed to stratify patients as having either low (papillary thyroid cancer confined to thyroid), intermediate (regional metastases, worrisome histologies, extrathyroidal extension, or vascular invasion), or high (gross extrathyroidal extension, distant metastases, or postoperative serum Tg suggestive of distant metastases) risk of recurrence, primarily based upon clinicopathologic findings  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. The risk of recurrence, however, follows a continuum across the three discrete risk categories (low, intermediate, and high). Additional prognostic variables (eg, extent of lymph node involvement, degree of vascular invasion in follicular thyroid cancer) were included in a modified version of the risk stratification system, although the additional variables have not been rigorously evaluated. This topic is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'ATA risk stratification'</a>.)</p><p></p><p class="bulletIndent1">Serum-specific molecular profiles (eg, BRAF, TERT) may be used to predict risk of extrathyroidal extension, lymph node metastases, and even distant metastases. While these observations need further validation, it is likely that the specific molecular profile of the primary tumor may have significant prognostic value that could be incorporated into the stratification systems. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'Molecular characteristics'</a>.)</p><p></p><p class="bulletIndent1">While initial risk stratification can be used to guide initial therapeutic and diagnostic follow-up strategy decisions, it is important to recognize that initial risk estimates may need to change as new data are accumulated during follow-up. (See <a class="local">'Dynamic risk stratification'</a> below.)</p><p></p><p class="headingAnchor" id="H51434041"><span class="h1">SUBSEQUENT MANAGEMENT BASED ON RISK CLASSIFICATION</span><span class="headingEndMark"> — </span>Postoperative management includes treatment with thyroid hormone suppressive therapy (most patients) and radioiodine (high-risk and selected intermediate-risk patients). Postoperative management depends upon the risk of recurrence/persistent disease  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). (See <a class="local">'Risk classification'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h2">Thyroid hormone suppression</span><span class="headingEndMark"> — </span>After initial thyroidectomy, whether or not radioiodine therapy is administered, thyroid hormone (T4 [<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>]) therapy is required in most patients to prevent hypothyroidism and to minimize potential TSH stimulation of tumor growth.</p><p>Our approach for initial thyroid hormone suppression is based upon risk of disease recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>American Thyroid Association (ATA) low risk</strong> – For patients with low-risk disease treated with thyroidectomy who have detectable serum thyroglobulin (Tg) levels (with or without remnant ablation), the serum TSH initially can be maintained between 0.1 and 0.5 mU/L. For similar patients who have undetectable serum Tg levels (with or without remnant ablation) or who were treated with lobectomy, TSH can be maintained in the mid to lower half of the reference range (0.5 to 2.0 mU/L). In the latter setting, thyroid hormone treatment may be unnecessary if a patient can maintain their TSH in this range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATA intermediate risk</strong> – For patients with intermediate-risk disease, the serum TSH initially can be maintained between 0.1 and 0.5 mU/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATA high risk</strong> – For patients with high-risk disease, the serum TSH initially should be less than 0.1 mU/L.</p><p></p><p>TSH goals for long-term follow-up are based on response to therapy assessments further modified by comorbid conditions that increase the potential risks of prolonged TSH suppression (such as menopause, tachycardia, osteopenia, older age, osteoporosis, or atrial fibrillation)  (<a class="graphic graphic_figure graphicRef118021" href="/z/d/graphic/118021.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. The dose also may be decreased to allow the TSH to rise into the normal range in intermediate-risk patients who demonstrate an excellent response to therapy. (See <a class="local">'Monitoring response to therapy'</a> below.)</p><p>The hypothesis that reduction of serum TSH concentrations to below the normal range decreases morbidity and mortality in all patients with differentiated thyroid cancer has not been proven, but some retrospective studies suggested improved relapse-free survival when serum TSH concentrations were undetectable during follow-up [<a href="#rid11">11,12</a>]. In reports from the National Thyroid Cancer Treatment Cooperative Study (NTCTCS, a multicenter prospective tumor registry), greater TSH suppression was associated with improved progression-free survival in high-risk papillary cancer patients [<a href="#rid13">13,14</a>], whereas milder degrees of TSH suppression were still associated with excellent outcomes in patients with intermediate-risk features  (<a class="graphic graphic_table graphicRef67832" href="/z/d/graphic/67832.html" rel="external">table 3</a>) [<a href="#rid14">14</a>]. In a follow-up report from the NTCTCS, a moderate degree of TSH suppression (TSH in the low normal to just below normal reference range) was associated with improved overall and disease-free survival in all stages, even in those with distant metastatic disease [<a href="#rid15">15</a>]. There was no additional survival benefit with aggressive TSH suppression (TSH undetectable to subnormal).</p><p>In a randomized trial of suppressive versus replacement therapy in 433 Japanese patients with papillary thyroid cancer [<a href="#rid16">16</a>], with achieved mean TSH levels of 0.07 and 3.19 mU/L, respectively, disease-free five-year survival, recurrence rates, and sites of recurrence were not significantly different between the two groups. However, these data might not be generalizable, since the majority of the participants had lobectomies and prophylactic central neck dissections and some had prophylactic lateral neck dissections, forms of surgery generally not done in most Western countries.</p><p>These findings, combined with the risks of overly aggressive T4 therapy, including the potential for acceleration of bone loss [<a href="#rid17">17-19</a>], atrial fibrillation [<a href="#rid20">20</a>], and cardiac dysfunction [<a href="#rid21">21-23</a>], emphasize the importance of tailoring the T4 dose to the extent of the disease and the likelihood of recurrence [<a href="#rid24">24</a>]. These decisions can be based in part upon staging by the tumor, node, metastases (TNM) system  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>) in conjunction with the proposed ATA risk of recurrence system  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. (See <a class="local">'Risk classification'</a> above and  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging"</a>.)</p><p class="headingAnchor" id="H3438702415"><span class="h2">Radioiodine therapy</span><span class="headingEndMark"> — </span>Radioiodine is administered after thyroidectomy in patients with differentiated thyroid cancer to ablate residual normal thyroid tissue (remnant ablation), provide adjuvant therapy of subclinical micrometastatic disease, and/or provide treatment of clinically apparent residual or metastatic thyroid cancer. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Goals'</a>.)</p><p>The decision to treat with radioiodine depends upon the risk of recurrence/persistent disease  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Patient selection'</a>.)</p><p>We routinely administer radioiodine after total thyroidectomy in high-risk patients and in selected intermediate-risk patients, depending upon specific tumor characteristics (eg, clinically significant lymph node metastases outside of the thyroid bed, or other higher-risk features).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATA low-risk disease</strong> – In the absence of a proven benefit on either disease-free survival or recurrence, we do not routinely administer radioiodine for remnant ablation to patients with low-risk disease, especially patients with unifocal tumors &lt;1 cm without other high-risk features or multifocal cancer when all foci are &lt;1 cm in the absence of other high-risk features, even in the presence of small-volume regional lymph node metastases (less than five lymph nodes measuring less than 2 mm).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATA</strong> <strong>intermediate-risk disease</strong> – We suggest postoperative radioiodine ablation to selected intermediate-risk patients, including those with clinically significant lymph node metastases outside of the thyroid bed; vascular invasion; or more aggressive histologic subtypes such as tall cell, columnar cell, insular, or poorly differentiated histologies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATA high-risk disease</strong> – We recommend postoperative radioiodine ablation to patients with high-risk disease, including patients with distant metastases, macroscopic tumor invasion, and/or incomplete tumor resection with gross residual disease.</p><p></p><p>The data to support these recommendations, patient preparation, dosing, monitoring, and complications of radioiodine treatment are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment"</a>.)</p><p class="headingAnchor" id="H3551171856"><span class="h2">Role of adjuvant external beam radiation therapy</span><span class="headingEndMark"> — </span>External beam radiotherapy (EBRT) can be used as adjuvant therapy after macroscopically complete surgical excision to prevent recurrence, particularly for older patients with gross extrathyroid extension at the time of surgery or selected younger patients with extensive disease and poor histologic features (eg, insular or poorly differentiated histology) whose disease is resected but in whom there is a high likelihood of residual microscopic disease. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a>.)</p><p class="headingAnchor" id="H4610264"><span class="h1">MONITORING RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>Monitoring strategies are based upon the patient's American Thyroid Association (ATA) risk of recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) and the reassessment of response to therapy at each follow-up visit. This strategy is in keeping with the ATA guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1372180109"><span class="h2">Dynamic risk stratification</span><span class="headingEndMark"> — </span>While initial staging systems can be used to guide initial therapeutic and diagnostic follow-up strategy decisions, it is important to recognize that initial risk estimates may need to change as new data are accumulated during follow-up [<a href="#rid25">25</a>]. In our practice, we restratify patients on each follow-up visit using a reclassification system that emphasizes the response to therapy for each individual patient. The response to therapy is assessed primarily with ultrasonography and measurements of serum thyroglobulin (Tg). (See <a class="local">'Initial monitoring during year 1'</a> below.)</p><p>As originally conceived, these clinical outcomes described the best response to initial therapy during the first two years of follow-up [<a href="#rid25">25,26</a>], but are now being used to describe the clinical status at any point during follow-up. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'Dynamic risk stratification'</a>.)</p><p>At each follow-up visit, patients are classified as having one of the following clinical outcomes  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>) [<a href="#rid26">26,27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excellent response</strong> – No clinical, biochemical, or structural evidence of disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical incomplete response</strong> – Abnormal Tg or rising Tg antibody values in the absence of localizable disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structural incomplete response</strong> – Persistent or newly identified locoregional or distant metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indeterminate response</strong> – Nonspecific biochemical or structural findings that cannot be confidently classified as either benign or malignant. This includes patients with stable or declining antithyroglobulin (anti-Tg) antibody levels without definitive structural evidence of disease.</p><p></p><p>The precise definition of type of response is dependent on the extent of initial therapy  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>).</p><p>Reclassification at each follow-up visit allows clinician to tailor ongoing management recommendations to the current clinical status (rather than the initial risk stratification estimates)  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef89724" href="/z/d/graphic/89724.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'Dynamic risk stratification'</a>.)</p><p class="headingAnchor" id="H4608945"><span class="h2">Initial monitoring during year 1</span><span class="headingEndMark"> — </span>For the detection of possible persistent/recurrent disease during the first year after thyroidectomy or lobectomy, we monitor [<a href="#rid1">1,2,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Neck ultrasound</p><p class="bulletIndent1"><span class="glyph">●</span>TSH</p><p class="bulletIndent1"><span class="glyph">●</span>Serum Tg levels on thyroid hormone suppression</p><p></p><p>Serum Tg on thyroid hormone suppression is generally measured every three to six months for the first year, with ultrasound at 6- to 12-month intervals depending on initial risk assessment  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Thyroid cancer follow-up'</a>.)</p><p>Additional imaging (cross-sectional or function imaging [eg, magnetic resonance imaging (MRI), computed tomography (CT), fludeoxyglucose-positron emission tomography (FDG-PET)]) is usually reserved only for  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a>) (see <a class="local">'Imaging'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>ATA high-risk patients  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) who typically have either a biochemical or structural incomplete response to therapy</p><p class="bulletIndent1"><span class="glyph">●</span>ATA low/intermediate-risk patients who demonstrate a structural or biochemical incomplete response to therapy during the first year of follow-up</p><p></p><p>These patients require further evaluation to identify residual disease, with consideration for additional therapies. In general, gross residual disease (structural incomplete response) in cervical lymph nodes identified by physical examination or ultrasound should be confirmed by fine-needle aspiration (FNA) and surgical resection considered. (See <a class="local">'Management of persistent or recurrent disease'</a> below.)</p><p>Diagnostic whole-body radioiodine scanning may still have a role in the follow up of higher-risk patients. (See <a class="local">'Diagnostic whole-body scan'</a> below.)</p><p class="headingAnchor" id="H4608981"><span class="h3">Serum thyroglobulin measurements</span><span class="headingEndMark"> — </span>Serum Tg levels are used to monitor patients with differentiated thyroid cancer for persistent or recurrent disease after initial therapy (lobectomy, thyroidectomy with or without radioiodine ablation)  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/2193.html" rel="external">"Differentiated thyroid cancer: Role of serum thyroglobulin", section on 'Monitoring response to therapy'</a>.)</p><p>In the first year after treatment of differentiated thyroid cancer, we measure thyroid hormone-suppressed serum Tg and Tg antibodies every three to six months. Serial Tg measurements should be performed using the same assay. Use of an assay with a functional sensitivity of 0.05 to 0.1 ng/mL is preferable. Anti-Tg antibodies, present initially in approximately 25 percent of patients with thyroid cancer, interfere with all assays for Tg. As a result, we measure anti-Tg antibodies, using the same assay over time, with each measurement of serum Tg. Tg assays are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2193.html" rel="external">"Differentiated thyroid cancer: Role of serum thyroglobulin", section on 'Thyroglobulin assay'</a>.)</p><p>Serum Tg can be measured while taking suppressive doses of thyroid hormone (TSH suppressed) or with TSH stimulation (after thyroid hormone withdrawal or after administration of recombinant human TSH [rhTSH (thyrotropin alfa)]). Stimulated Tg measurements are generally not necessary in ATA low-risk patients who do not receive radioiodine to ablate thyroid remnants, or in ATA intermediate/high-risk patients who have a detectable Tg on suppression (ie, evidence of biochemical incomplete response to therapy). Stimulated Tg values are useful in ATA intermediate- and high-risk patients with an undetectable suppressed Tg to document an excellent response to therapy or, conversely, to identify the presence of persistent/recurrent disease [<a href="#rid29">29</a>].</p><p>In the newer, more sensitive Tg assays (functional sensitivity &lt;0.05 ng/mL), serum Tg concentrations (measured while receiving T4 [<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>] suppression therapy) correlate with rhTSH-stimulated Tg concentrations and, therefore, may decrease the need for rhTSH-stimulated measurements [<a href="#rid30">30-34</a>].</p><p>The interpretation of the serum Tg level depends upon the initial therapy  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H4608988"><span class="h4">Thyroidectomy with 131-I ablation</span><span class="headingEndMark"> — </span>For patients who had a total thyroidectomy and radioiodine remnant ablation, an excellent response is a nonstimulated Tg &lt;0.2 ng/mL (or TSH-stimulated Tg &lt;1 ng/mL)  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H4608995"><span class="h4">Thyroidectomy without 131-I ablation</span><span class="headingEndMark"> — </span>For patients who have had total or near-total thyroidectomy without radioiodine ablation, an excellent response is a nonstimulated Tg &lt;0.2 ng/mL (or TSH-stimulated Tg &lt;2 ng/mL). The interpretation of serum Tg levels may be difficult in this subset of patients as it depends upon the size of the thyroid remnant [<a href="#rid35">35</a>]. Many patients do have undetectable basal Tg levels (&lt;0.2 ng/mL), and basal serum Tg (along with anti-Tg antibodies) should be measured in such patients as rising values over time are suspicious for growing thyroid tissue or cancer  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2193.html" rel="external">"Differentiated thyroid cancer: Role of serum thyroglobulin", section on 'Predictor of clinical outcomes'</a>.)</p><p class="headingAnchor" id="H3882188262"><span class="h4">Lobectomy</span><span class="headingEndMark"> — </span>Periodic measurement of serum Tg should also be performed in patients who were treated with lobectomy. Although specific criteria for distinguishing normal residual thyroid tissue from persistent or recurrent thyroid cancer have not been defined, most patients with an excellent response should have a serum Tg level &lt;30 ng/mL  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>) [<a href="#rid36">36,37</a>]. Previously, a rising Tg value over time was considered to be a reliable marker of recurrent disease. However, subsequent studies have demonstrated that changes in serum Tg over time are not reliable indicators of recurrent disease and that rising Tg levels are more likely to be related to residual thyroid tissue/nodules than to a true structural disease recurrence [<a href="#rid38">38-40</a>].</p><p class="headingAnchor" id="H4609002"><span class="h4">Thyroglobulin antibodies</span><span class="headingEndMark"> — </span>In patients with anti-Tg antibodies, serum Tg concentrations alone cannot be used as a marker to detect persistent or recurrent disease after thyroidectomy and ablation of residual normal thyroid tissue. Nevertheless, we measure serum Tg and anti-Tg antibodies as we do in patients without anti-Tg antibodies because disease recurrence can be heralded by a rise in Tg antibodies with or without a corresponding rise in serum Tg, and conversely, a significant fall in these titers suggests future recurrence is unlikely [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/2193.html" rel="external">"Differentiated thyroid cancer: Role of serum thyroglobulin", section on 'Surrogate tumor marker'</a>.)</p><p>In high-risk patients with persistent positive anti-Tg antibodies, imaging in addition to neck ultrasound (including neck and chest CT and/or PET-CT) may be warranted to detect structural disease.</p><p class="headingAnchor" id="H4609009"><span class="h3">Imaging</span><span class="headingEndMark"> — </span>Neck ultrasound is performed at 6- to 12-month intervals depending on risk assessment  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a>). Ultrasonography has been particularly useful at identifying malignant cervical lymph nodes, the most common site of recurrent papillary thyroid cancer. Ultrasonographic lymph node characteristics most consistent with malignancy are a cystic appearance, microcalcifications, loss of the normal fatty hilum, and peripheral vascularization  (<a class="graphic graphic_diagnosticimage graphicRef90884" href="/z/d/graphic/90884.html" rel="external">image 1</a>) [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Thyroid cancer'</a>.)</p><p>If there is biochemical or ultrasound evidence of recurrence, other tests that may be indicated to identify the sites of disease include a diagnostic whole-body scan (radioiodine imaging on a low-iodine diet with TSH stimulation), CT or MRI, skeletal radiographs, or skeletal radionuclide imaging [<a href="#rid43">43</a>]. In patients with evidence of distant metastases, FDG-PET scanning may provide useful prognostic information [<a href="#rid44">44</a>]. This was illustrated in a study of 125 patients with well-differentiated thyroid cancer who underwent FDG-PET scanning; uptake of FDG in a large volume of tissue correlated with poor survival, predicting outcome better than uptake of radioiodine.</p><p>In most studies, T4 therapy was not withdrawn before FDG-PET scanning was done, but in one small study, more lesions were identified after therapy was withdrawn [<a href="#rid45">45</a>]. The use of rhTSH before FDG-PET scan significantly increases the number of lesions detected, but treatment changes due to true positive lesions are uncommon (6 percent in one study of 63 patients) [<a href="#rid46">46</a>].</p><p>FDG-PET may complement iodine-131 (131-I) scanning [<a href="#rid47">47</a>]. In a study of 239 patients with metastases and high Tg, the sensitivity of FDG-PET was 49 percent, the sensitivity of 131-I was 50 percent, and the combined sensitivity was 90 percent. FDG-PET was more likely to be positive in 131-I negative patients [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H4609016"><span class="h3">Diagnostic whole-body scan</span><span class="headingEndMark"> — </span>Diagnostic whole-body radioiodine scanning may have a role in the follow-up of patients with high or intermediate risk (with higher-risk features) of persistent disease  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). However, we are in agreement with the ATA guidelines that routine follow-up diagnostic whole-body scanning one year after radioiodine ablation is not required in low- and intermediate-risk (with lower-risk features) patients  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a>) [<a href="#rid1">1</a>].</p><p>Two studies [<a href="#rid49">49,50</a>], but not a third [<a href="#rid51">51</a>], suggested that whole-body scanning is unnecessary if rhTSH-stimulated serum Tg concentrations are less than 2 ng/mL. Another study reported that a combination of rhTSH-stimulated Tg and neck ultrasound has a better predictive value than either rhTSH-stimulated Tg alone or in combination with radioiodine scanning [<a href="#rid52">52</a>].</p><p>When diagnostic radioiodine scanning is performed, we suggest using rhTSH stimulation for radioactive iodine scanning when the likelihood of requiring additional radioactive iodine therapy is low. If the patient is very likely to need additional radioiodine therapy (high-risk patients), thyroid hormone withdrawal is the preferred approach. This topic is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Choice of method for increasing TSH'</a> and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Pretreatment scanning'</a>.)</p><p class="headingAnchor" id="H654847"><span class="h2">Ongoing monitoring after year 1</span><span class="headingEndMark"> — </span>Ongoing follow-up (neck ultrasound, serum Tg) is guided by assessment of the individual patient's response to therapy during the first one to two years of follow-up  (<a class="graphic graphic_table graphicRef89724" href="/z/d/graphic/89724.html" rel="external">table 6</a>). Most recurrences of differentiated thyroid cancer occur within the first five years after initial treatment, but recurrences may occur many years or even decades later, particularly in patients with papillary cancer [<a href="#rid53">53</a>]. Nonetheless, continued routine use of surveillance neck ultrasound in ATA low- to intermediate-risk patients with no biochemical or clinical evidence of disease is more likely to identify false-positive findings than true structural disease recurrence [<a href="#rid54">54,55</a>].</p><p>A serum TSH is measured annually and six to eight weeks after any dose adjustments of T4. Although the serum TSH should be maintained &lt;0.1 mU/L in patients with a structurally incomplete response  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>), patients with a better response to therapy can have their TSH goal raised [<a href="#rid1">1</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who initially presented with high-risk disease but who have an excellent or indeterminate clinical response to therapy, a TSH goal of 0.1 to 0.5 mU/L for up to five years is acceptable, after which time the degree of suppression can be further relaxed (with continued surveillance for recurrence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who initially presented with low-risk disease and who have an excellent clinical response to therapy, a TSH goal of 0.5 to 2 mU/L is acceptable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a biochemically incomplete response, the serum TSH should be maintained between 0.1 and 0.5 mU/L.</p><p></p><p class="headingAnchor" id="H3695181974"><span class="h1">MANAGEMENT OF PERSISTENT OR RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Recurrent tumor in the neck may be detected by clinical examination or rising serum thyroglobulin (Tg) concentrations, but ultrasonography is the most sensitive technique for localization  (<a class="graphic graphic_diagnosticimage graphicRef90884" href="/z/d/graphic/90884.html" rel="external">image 1</a>) [<a href="#rid35">35,56</a>]. (See <a class="local">'Imaging'</a> above and  <a class="medical medical_review" href="/z/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Thyroid cancer follow-up'</a>.)</p><p>Highly sensitive detection tools (such neck ultrasonography, computer tomography [CT] scans, magnetic resonance imaging [MRI], and highly sensitive serum thyroglobulin assays) can identify very small volume persistent or recurrent disease that may not demand immediate intervention. Thus, we differentiate "detectable findings" from "actionable findings" [<a href="#rid57">57</a>]. The key factors that differentiate detectable from actionable findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor size (volume)</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor location</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor growth rate (biochemical or structural doubling time)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Patient preference</p><p></p><p class="headingAnchor" id="H2931460221"><span class="h2">Minimal disease</span><span class="headingEndMark"> — </span>Although many patients will still have abnormal serum Tg levels after surgery, indicating a persistence of detectable disease, surgery is not always indicated.</p><p>Surgical resection is typically reserved for patients with clinically significant, low-volume metastatic disease, eg, central neck lymph nodes at least &gt;0.8 cm in diameter or, possibly, larger nodes in the lateral compartments (&gt;1.5 to 2 cm), especially if they are increasing in size (more than 3 to 5 mm in any dimension) or are significantly fludeoxyglucose-positron emission tomography (FDG-PET) positive (standardized uptake value [SUV] 5 to 10). However, we recognize that aggressive surgical resection of small-volume disease in the central or lateral neck does not have a proven benefit in terms of improving overall survival. Therefore, it is important to ensure that the risk of persistent low-level disease outweighs the risk of surgical resection in patients with potentially stable low-volume disease.</p><p>Surgery is usually followed by a reevaluation of the clinical status, which always includes serum Tg determinations, may include radioiodine scanning, and, if there is persistent radioiodine uptake, radioiodine therapy. However, if the patient had a recombinant human thyroid-stimulating hormone (rhTSH [thyrotropin alfa])-stimulated radioiodine scan before such surgery and if gross recurrent disease failed to concentrate radioiodine before surgery, there is likely no role for postoperative imaging and radioiodine therapy. Recurrent disease that is FDG avid (positive on FDG-PET scanning) is unlikely to respond to even high-dose radioiodine therapy [<a href="#rid58">58</a>]. (See <a class="local">'High serum thyroglobulin and negative radioiodine scan'</a> below.)</p><p class="headingAnchor" id="H2614545878"><span class="h2">Extensive disease</span><span class="headingEndMark"> — </span>Recurrence within the thyroid bed may be associated with soft-tissue, laryngeal, tracheal, or esophageal invasion, which may require more extensive resection; imaging studies with contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) may be valuable to detect such locally extensive disease. (See <a class="local">'Imaging'</a> above and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Surgery for invasive disease'</a>.)</p><p>Patients who develop distant metastases during long-term follow-up are treated like those with metastases found at the time of initial treatment; however, radioiodine therapy may be less effective in these patients [<a href="#rid59">59</a>]. (See <a class="local">'Subsequent management based on risk classification'</a> above.)</p><p>Other options for treating recurrent/metastatic disease include the following [<a href="#rid60">60-63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Radioiodine, if scans demonstrate uptake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic chemotherapy (eg, kinase inhibitors).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>External radiotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous ethanol injection of cervical nodal metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiofrequency ablation of cervical, osseous, and pulmonary metastases – This is an alternative for patients who are poor surgical candidates and whose metastases do not concentrate radioiodine, but expertise in this treatment modality is not widely available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palliative embolization of bone metastases – Palliative embolization may reduce symptoms or be used prior to surgery.</p><p></p><p>Surgery may be considered for patients with single distant metastases, including patients with a single bone metastasis [<a href="#rid64">64</a>], brain metastases [<a href="#rid65">65</a>], or limited pulmonary metastases [<a href="#rid66">66</a>]. The five-year survival for 31 patients with papillary cancer after thoracic metastasectomy was 64 percent [<a href="#rid66">66</a>], and radical surgical extirpation of isolated bone metastases is associated with improved survival [<a href="#rid67">67</a>].</p><p><a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">Pamidronate</a> may reduce bone pain from skeletal metastases and improve quality of life, and in one study, resulted in partial radiologic improvement in 2 of 10 patients [<a href="#rid68">68</a>]. <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">Zoledronic acid</a> can also be used, although its greater potency may increase risk of hypocalcemia and osteonecrosis of the jaw (ONJ) (although this remains a rare complication) [<a href="#rid69">69,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy", section on 'Osteonecrosis of the jaw'</a>.)</p><p><a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> (a receptor activator of nuclear factor kappa-B [RANK] ligand inhibitor) is also available for the prevention of skeletal related events (pathologic fracture, need for surgery or external beam irradiation to a bone metastasis, or spinal cord compression) in patients with bone metastases from solid tumors. Thus, denosumab is an alternative to bisphosphonate therapy in the management of thyroid cancer patients with bone metastases [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Denosumab'</a>.)</p><p>Systemic chemotherapy or palliative external radiotherapy may be considered for patients with either local or distant recurrence or when radioiodine fails to control local growth and spread of disease. (See  <a class="medical medical_review" href="/z/d/html/2191.html" rel="external">"Differentiated thyroid cancer refractory to standard treatment: Systemic therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a>.)</p><p class="headingAnchor" id="H3233017616"><span class="h2">High serum thyroglobulin and negative radioiodine scan</span><span class="headingEndMark"> — </span>It is not uncommon to identify patients who have abnormal serum Tg values after total thyroidectomy and radioiodine ablation with no evidence of radioiodine avidity on diagnostic and, often, post-therapy radioiodine scans [<a href="#rid72">72,73</a>]. These false-negative scans may reflect inadequate TSH stimulation, iodine contamination, the presence of tumor deposits too small to be detected by a scintillation camera, or loss of iodine uptake through tumor dedifferentiation.</p><p>The management of such patients is controversial, and there are insufficient data to determine optimal therapy [<a href="#rid74">74</a>].</p><p>Our approach to patients with radioiodine-negative, serum Tg-positive disease is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of 24-hour urinary iodine excretion to exclude exogenous iodine excess causing a false-negative scan.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neck ultrasound and neck and chest CT (without iodinated contrast).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In high-risk patients or those in whom the basal or stimulated Tg is ≥10 ng/mL, additional imaging studies should be performed to include whole-body FDG-PET scan (preferably combined with CT imaging).</p><p></p><p class="bulletIndent1">In various studies, ultrasonography [<a href="#rid75">75,76</a>], CT [<a href="#rid75">75</a>], MRI [<a href="#rid77">77</a>], or scintigraphy with 111-indium-penetreotide, 99m-technetium-sestamibi, or 99m-technetium-tetrafosmin [<a href="#rid78">78-80</a>] detected foci of cancer in from 25 to 50 percent of patients with negative diagnostic radioiodine scans. Distant metastases can also be identified by chest and bone radiographs [<a href="#rid81">81</a>]. In addition, FDG-PET may be useful. In a review of PET imaging in scan-negative patients that summarized 12 studies, sensitivity ranged from 60 to 95 percent and specificity from 25 to 90 percent [<a href="#rid82">82</a>]. Metastatic lesions with high avidity for glucose in PET imaging, measured by elevated standard uptake values, are associated with resistance to radioiodine therapy and worse prognosis [<a href="#rid58">58,83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We agree with the American Thyroid Association (ATA) guidelines that radioiodine is usually not necessary in patients with nonstimulated Tg values &lt;5 ng/mL (or stimulated Tg values less than 10 ng/mL) in the absence of structurally evident disease. However, we will consider empiric radioiodine administration (100 to 200 mCi) in patients with radiographically detectable micrometastatic pulmonary metastases that do not concentrate FDG on PET imaging or with progressively rising Tg levels. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>External radiotherapy for patients with critically placed bone metastases. (See  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with progressive macrometastatic disease unresponsive to radioiodine should be considered for systemic therapy or an appropriate clinical trial.</p><p></p><p>Studies show 42 to 75 percent of patients with high serum Tg and negative diagnostic radioiodine scans had demonstrable uptake, most often in the neck and mediastinum, after administration of a high dose (therapeutic dose) of radioiodine (eg, 150 mCi [5550 MBq]) [<a href="#rid75">75,84,85</a>]. Distant metastases were more often identified in patients with higher serum Tg concentrations (&gt;200 ng/mL) [<a href="#rid84">84</a>]. In a study of 27 patients with negative diagnostic scans and positive post-treatment scans, 56 percent had progressive disease that did not respond to radioiodine, while 44 percent had stable disease that did not regress after radioiodine [<a href="#rid86">86</a>].</p><p>In some [<a href="#rid72">72,84,85,87</a>], but not all [<a href="#rid88">88</a>], studies, radioiodine administration resulted in reductions in serum Tg concentrations in patients with high serum Tg and negative diagnostic radioiodine scans, but there is no evidence that the treatment affects prognosis. Furthermore, when there is no structural evidence of disease, observation with T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) suppression is often associated with a slow decline in Tg levels over many years. These observations question whether empiric radioiodine therapy for scan-negative, Tg-positive patients has any significant clinical benefit beyond improved disease localization [<a href="#rid50">50,74,89,90</a>].</p><p class="headingAnchor" id="H3669118"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most patients with papillary cancer do not die of their disease. However, a number of factors have been identified that are associated with a higher risk for tumor recurrence and cancer-related mortality. The most important prognostic factors are age at diagnosis, size of the primary tumor, and the presence of soft tissue invasion or distant metastases  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Prognostic features'</a>.)</p><p>When compared with papillary thyroid cancer, follicular cancer typically occurs in older patients. In addition, it is more commonly associated with an aggressive clinical course, distant metastases, and higher mortality than papillary thyroid cancer. Women may have a better prognosis than men. (See  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)", section on 'Prognostic features'</a>.)</p><p class="headingAnchor" id="H3484184049"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113808.html" rel="external">"Society guideline links: Thyroid nodules and cancer"</a>.)</p><p class="headingAnchor" id="H21595425"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82979.html" rel="external">"Patient education: Thyroid cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> – The primary therapy for differentiated (papillary and follicular) thyroid cancer is surgery. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preoperative imaging</strong> – All patients should have a preoperative ultrasound evaluation of the central and lateral neck lymph nodes in order to plan the surgical procedure. Additional imaging beyond routine preoperative neck ultrasound should be obtained in patients presenting with locally advanced disease. (See <a class="local">'Preoperative imaging'</a> above and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Importance of preoperative imaging'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of surgical procedure</strong> – Surgical options include total/near-total thyroidectomy and unilateral lobectomy with isthmusectomy. The operative approach depends upon the extent of the disease (eg, primary tumor size and the presence of extrathyroidal extension or lymph node metastases), the patient's age, and the presence of comorbid conditions. Subtotal thyroidectomy is an inadequate procedure for patients with thyroid cancer. (See <a class="local">'Choice of surgical procedure'</a> above and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Choice of procedure'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative thyroid hormone replacement</strong> – After total thyroidectomy, all patients require postoperative thyroid hormone therapy (T4 [<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>]) to replace normal hormone production and/or to suppress regrowth of tumor. Thyroid-stimulating hormone (TSH) is measured four to six weeks postoperatively, and the initial dose is adjusted as needed to achieve goal TSH. For selected low- and intermediate-risk patients whose initial surgery was a lobectomy, we measure serum TSH six weeks after surgery and determine the need for T4 based upon the TSH and evaluation of postoperative disease status. (See <a class="local">'Postoperative thyroid hormone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial risk stratification</strong> – In order to determine the need for additional treatment (in particular, radioiodine therapy) after surgery, we use the American Thyroid Association (ATA) initial risk stratification system to estimate the risk of persistent/recurrent disease. This system is designed to stratify patients as having either low (papillary thyroid cancer confined to thyroid), intermediate (regional metastases, worrisome histologies, extrathyroidal extension, or vascular invasion), or high (gross extrathyroidal extension, distant metastases, or postoperative serum thyroglobulin [Tg] suggestive of distant metastases) risk of recurrence primarily based upon clinicopathologic findings  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). (See <a class="local">'Postoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management based on risk stratification</strong> – Subsequent management includes treatment with thyroid hormone-suppressive therapy (most patients) and radioiodine (high-risk and selected intermediate-risk patients). (See <a class="local">'Thyroid hormone suppression'</a> above and <a class="local">'Radioiodine therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Patient selection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid hormone suppression</strong> – The initial degree of TSH suppression is individualized based upon the extent of the disease and the likelihood of recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). TSH goals for long-term follow-up are based on response to therapy assessments further modified by comorbid conditions that increase the potential risks of prolonged TSH suppression (such as menopause, tachycardia, osteopenia, older age, osteoporosis, or atrial fibrillation)  (<a class="graphic graphic_figure graphicRef118021" href="/z/d/graphic/118021.html" rel="external">figure 1</a>). (See <a class="local">'Thyroid hormone suppression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-risk disease</strong> – For most patients with high-risk disease, we recommend an initial serum TSH goal of &lt;0.1 mU/L (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intermediate- or low-risk disease</strong> – For patients with intermediate-risk disease, or low-risk disease treated with thyroidectomy who have detectable serum Tg levels, we suggest an initial serum TSH goal between 0.1 and 0.5 mU/L (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">For other low-risk patients who have undetectable serum Tg levels (with or without remnant ablation) or who were treated with lobectomy, TSH can be maintained in the mid to lower half of the reference range (0.5 to 2.0 mU/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Ongoing monitoring strategies are based upon the patient's ATA risk of recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) and the reassessment of response to therapy at each follow-up visit  (<a class="graphic graphic_table graphicRef105369" href="/z/d/graphic/105369.html" rel="external">table 4</a>). (See <a class="local">'Dynamic risk stratification'</a> above.)</p><p></p><p class="bulletIndent1">For the detection of possible persistent/recurrent disease during the first year after thyroidectomy or lobectomy, we monitor neck ultrasound, TSH, and serum Tg levels on thyroid hormone suppression. The timing, frequency, and type of additional testing used to detect recurrent disease is based on both ATA initial risk stratification and ongoing response to therapy evaluations  (<a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef89724" href="/z/d/graphic/89724.html" rel="external">table 6</a>). (See <a class="local">'Initial monitoring during year 1'</a> above and <a class="local">'Ongoing monitoring after year 1'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent or recurrent disease</strong> – Options for treating recurrent/metastatic disease include surgery, radioiodine (if scans demonstrate uptake), chemotherapy, and external radiotherapy. (See <a class="local">'Management of persistent or recurrent disease'</a> above and  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2191.html" rel="external">"Differentiated thyroid cancer refractory to standard treatment: Systemic therapy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/default.aspx.</li><li><a class="nounderline abstract_t">Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787.</a></li><li><a class="nounderline abstract_t">Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2007; 5:568.</a></li><li><a class="nounderline abstract_t">Cobin RH, Gharib H, Bergman DA, et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001; 7:202.</a></li><li class="breakAll">British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer, 2007. http://www.british-thyroid-association.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf (Accessed on December 10, 2012).</li><li><a class="nounderline abstract_t">McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 2013; 381:1046.</a></li><li><a class="nounderline abstract_t">Adam MA, Thomas S, Youngwirth L, et al. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes? Ann Surg 2016.</a></li><li><a class="nounderline abstract_t">Fogelfeld L, Wiviott MB, Shore-Freedman E, et al. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. N Engl J Med 1989; 320:835.</a></li><li><a class="nounderline abstract_t">Lee DY, Seok J, Jeong WJ, Ahn SH. Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res 2015; 193:273.</a></li><li><a class="nounderline abstract_t">Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81:4318.</a></li><li><a class="nounderline abstract_t">Diessl S, Holzberger B, Mäder U, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012; 76:586.</a></li><li><a class="nounderline abstract_t">Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8:737.</a></li><li><a class="nounderline abstract_t">Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229.</a></li><li><a class="nounderline abstract_t">Carhill AA, Litofsky DR, Ross DS, et al. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab 2015; 100:3270.</a></li><li><a class="nounderline abstract_t">Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab 2010; 95:4576.</a></li><li><a class="nounderline abstract_t">Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82:1167.</a></li><li><a class="nounderline abstract_t">Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990; 113:265.</a></li><li><a class="nounderline abstract_t">Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4:319.</a></li><li><a class="nounderline abstract_t">Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.</a></li><li><a class="nounderline abstract_t">Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 1995; 80:2222.</a></li><li><a class="nounderline abstract_t">Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77:334.</a></li><li><a class="nounderline abstract_t">Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78:1028.</a></li><li><a class="nounderline abstract_t">Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20:135.</a></li><li><a class="nounderline abstract_t">Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 2008; 37:419.</a></li><li><a class="nounderline abstract_t">Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20:1341.</a></li><li><a class="nounderline abstract_t">Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 2011; 75:112.</a></li><li><a class="nounderline abstract_t">Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433.</a></li><li><a class="nounderline abstract_t">Robenshtok E, Grewal RK, Fish S, et al. A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. Thyroid 2013; 23:436.</a></li><li><a class="nounderline abstract_t">Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007; 92:2487.</a></li><li><a class="nounderline abstract_t">Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007; 92:82.</a></li><li><a class="nounderline abstract_t">Iervasi A, Iervasi G, Ferdeghini M, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007; 67:434.</a></li><li><a class="nounderline abstract_t">Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 &lt; 1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 2008; 68:338.</a></li><li><a class="nounderline abstract_t">Spencer C, Fatemi S, Singer P, et al. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010; 20:587.</a></li><li><a class="nounderline abstract_t">Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006; 91:60.</a></li><li><a class="nounderline abstract_t">Momesso DP, Vaisman F, Yang SP, et al. Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. J Clin Endocrinol Metab 2016; 101:2692.</a></li><li><a class="nounderline abstract_t">Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43:401.</a></li><li><a class="nounderline abstract_t">Park S, Jeon MJ, Oh HS, et al. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer. Thyroid 2018; 28:997.</a></li><li><a class="nounderline abstract_t">Cho JW, Lee YM, Lee YH, et al. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients. Clin Endocrinol (Oxf) 2018; 89:100.</a></li><li><a class="nounderline abstract_t">Ritter A, Mizrachi A, Bachar G, et al. Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93:4683.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3590.</a></li><li><a class="nounderline abstract_t">Gagel RF, Goepfert H, Callender DL. Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 1996; 46:261.</a></li><li><a class="nounderline abstract_t">Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91:498.</a></li><li><a class="nounderline abstract_t">van Tol KM, Jager PL, Piers DA, et al. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002; 12:381.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009; 94:1310.</a></li><li><a class="nounderline abstract_t">Esteva D, Muros MA, Llamas-Elvira JM, et al. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Ann Surg Oncol 2009; 16:2006.</a></li><li><a class="nounderline abstract_t">Wang H, Fu HL, Li JN, et al. Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer. Clin Imaging 2008; 32:32.</a></li><li><a class="nounderline abstract_t">Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490.</a></li><li><a class="nounderline abstract_t">Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499.</a></li><li><a class="nounderline abstract_t">Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87:3242.</a></li><li><a class="nounderline abstract_t">Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:3668.</a></li><li><a class="nounderline abstract_t">Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118:1131.</a></li><li><a class="nounderline abstract_t">Peiling Yang S, Bach AM, Tuttle RM, Fish SA. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. J Clin Endocrinol Metab 2015; 100:1561.</a></li><li><a class="nounderline abstract_t">Verburg FA, Mäder U, Giovanella L, et al. Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and 131I Ablation. Thyroid 2018; 28:722.</a></li><li><a class="nounderline abstract_t">Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003; 97:90.</a></li><li><a class="nounderline abstract_t">Tuttle RM, Alzahrani AS. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. J Clin Endocrinol Metab 2019; 104:4087.</a></li><li><a class="nounderline abstract_t">Wang W, Larson SM, Tuttle RM, et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11:1169.</a></li><li><a class="nounderline abstract_t">Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996; 78:493.</a></li><li><a class="nounderline abstract_t">Hay ID, Charboneau JW. The coming of age of ultrasound-guided percutaneous ethanol ablation of selected neck nodal metastases in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2011; 96:2717.</a></li><li><a class="nounderline abstract_t">Lewis BD, Hay ID, Charboneau JW, et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002; 178:699.</a></li><li><a class="nounderline abstract_t">Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006; 244:296.</a></li><li><a class="nounderline abstract_t">Eustatia-Rutten CF, Romijn JA, Guijt MJ, et al. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:3184.</a></li><li><a class="nounderline abstract_t">Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001; 86:1568.</a></li><li><a class="nounderline abstract_t">Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637.</a></li><li><a class="nounderline abstract_t">Porterfield JR, Cassivi SD, Wigle DA, et al. Thoracic metastasectomy for thyroid malignancies. Eur J Cardiothorac Surg 2009; 36:155.</a></li><li><a class="nounderline abstract_t">Zettinig G, Fueger BJ, Passler C, et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy? Clin Endocrinol (Oxf) 2002; 56:377.</a></li><li><a class="nounderline abstract_t">Vitale G, Fonderico F, Martignetti A, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 2001; 84:1586.</a></li><li><a class="nounderline abstract_t">Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008; 15:37.</a></li><li><a class="nounderline abstract_t">Wexler JA, Sharretts J. Thyroid and bone. Endocrinol Metab Clin North Am 2007; 36:673.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on September 14, 2011).</li><li><a class="nounderline abstract_t">Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28:1888.</a></li><li><a class="nounderline abstract_t">Schlumberger M, Arcangioli O, Piekarski JD, et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29:1790.</a></li><li><a class="nounderline abstract_t">Ma C, Kuang A, Xie J. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev 2009; :CD006988.</a></li><li><a class="nounderline abstract_t">Pachucki J, Burmeister LA. Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur J Endocrinol 1997; 137:254.</a></li><li><a class="nounderline abstract_t">Franceschi M, Kusić Z, Franceschi D, et al. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37:446.</a></li><li><a class="nounderline abstract_t">Toubert ME, Cyna-Gorse F, Zagdanski AM, et al. Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits. Thyroid 1999; 9:591.</a></li><li><a class="nounderline abstract_t">Lind P, Gallowitsch HJ, Langsteger W, et al. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997; 38:348.</a></li><li><a class="nounderline abstract_t">Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996; 81:2541.</a></li><li><a class="nounderline abstract_t">Valli N, Catargi B, Ronci N, et al. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 1999; 9:583.</a></li><li><a class="nounderline abstract_t">Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37:598.</a></li><li><a class="nounderline abstract_t">Khan N, Oriuchi N, Higuchi T, et al. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003; 76:690.</a></li><li><a class="nounderline abstract_t">Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85:1107.</a></li><li><a class="nounderline abstract_t">Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488.</a></li><li><a class="nounderline abstract_t">Koh JM, Kim ES, Ryu JS, et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol (Oxf) 2003; 58:421.</a></li><li><a class="nounderline abstract_t">Sabra MM, Grewal RK, Tala H, et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid 2012; 22:877.</a></li><li><a class="nounderline abstract_t">Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86:4092.</a></li><li><a class="nounderline abstract_t">Schaap J, Eustatia-Rutten CF, Stokkel M, et al. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma? Clin Endocrinol (Oxf) 2002; 57:117.</a></li><li><a class="nounderline abstract_t">Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008; 4:223.</a></li><li><a class="nounderline abstract_t">Alzahrani AS, Raef H, Sultan A, et al. Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer. J Endocrinol Invest 2002; 25:526.</a></li></ol></div><div id="topicVersionRevision">Topic 7838 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728537" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17623612" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11430305" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11430305" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23668555" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Controversies in primary treatment of low-risk papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26967630" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2927450" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088372" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prediction of thyroid hormone supplementation after thyroid lobectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8954034" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22059804" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777742" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17199433" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outcomes of patients with differentiated thyroid carcinoma following initial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26171797" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660039" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605133" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375563" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833670" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hyperthyroidism, thyroid hormone therapy, and bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935681" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608283" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345037" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175955" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151821" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18502335" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Follow up approaches in thyroid cancer: a risk adapted paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21034228" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521273" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679418" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23067402" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426102" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17077133" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555505" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17850379" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4&lt;1 ng/ml determined by traditional assays?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470203" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219716" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27023446" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891169" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Update on differentiated thyroid cancer staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29845894" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29672893" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219303" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812478" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17609301" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8806393" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Changing concepts in the pathogenesis and management of thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303836" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12097198" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158200" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415387" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164392" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932270" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932271" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12107232" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915653" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7491533" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognostic factors and risk group analysis in follicular carcinoma of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25632970" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29665748" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and 131I Ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12491509" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874735" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186505" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697396" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21896899" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The coming of age of ultrasound-guided percutaneous ethanol ablation of selected neck nodal metastases in well-differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856701" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16858194" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843163" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297585" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360519" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prognosis and treatment of brain metastases in thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539179" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Thoracic metastasectomy for thyroid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940050" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401309" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310274" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bone metastases from differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673124" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thyroid and bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673124" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Thyroid and bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3681445" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3183748" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160311" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330589" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772642" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411122" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9074515" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675574" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411121" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8691248" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512328" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : PET in the follow-up of differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720047" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7744991" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12641624" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22827641" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549631" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100079" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268520" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12109624" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
